NanoVation-GS Overview
NanoVation-GS is a med-tech startup aiming to help alleviate the suffering of hundreds of millions of patients and reduce the high financial burden due to frequent hospitalizations of chronic respiratory patients such as COPD and asthma. SenseGuard™, developed by NanoVation-GS, is a reliable and patient-friendly solution for monitoring patients’ respiratory condition, measuring unique lung function biomarkers from effortless (tidal) breathing. Short measurements of 2-3 minutes once a day, enable disease management and early detection and treatment of exacerbations, before they reach acute stage that requires hospitalization.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
https://www.jpost.com/israel-news/article-712509
Israeli company NanoVation-GS has developed a nanosensor-based technology for monitoring and managing chronic respiratory conditions. The technology, discovered at the Technion, enables surveillance and early identification of changes in a patients condition, reducing hospitalizations and their duration. The device measures respiratory parameters without discomfort or effort from the patient. NanoVation-GS has completed successful clinical trials and obtained necessary regulatory approvals. The company plans to enter the COPD monitoring market in Europe and expand to other territories and applications in the future.
CustomersPartners
growth-positive
NanoVation receives $5.9 million from European Innovation Council Fund for its respiratory monitoring device
The European Innovation Council (EIC) Fund has invested €5 million ($5.9 million) in NanoVation, an Israeli medical startup developing respiratory monitoring technology. NanoVation is the first Israeli company to receive both a grant and equity funding from the EIC. The investment will support NanoVation in scaling up its breakthrough technology, SenseGuard, which is a respiratory monitor based on proprietary nano-sensor technology. SenseGuard aims to improve patients quality of life and treatment while reducing healthcare system costs. NanoVation has already received its CE Marking. The company was founded in 2014 and previously received €2.5 million ($2.9 million) from the European Unions Horizon 2020 EIC Accelerator program.
Investment
growth-positive
Israel medical startup NanoVation receives 2.5 million Euro grant from the European Union
Medical startup NanoVation has been awarded 2.5 million Euros ($2.8 million) by the European Union to develop a respiratory monitoring device for COPD. The device, called SenseGuard, is a wireless wearable medical device that monitors patient breathing. COPD is the third-leading cause of death globally, and the device aims to reduce the clinical and economic burden of the disease. NanoVation has already received its CE-marking and is currently being deployed in Israel and some EU countries. The grant is part of the Horizon 2020 EIC Accelerator Program, which supports breakthrough innovation projects from small and medium-sized businesses.
Investment
growth-positive
Israeli Startups Receive Grants to Develop Early Detection Devices for Pneumonia
Two Israeli startups, RespiDX and NanoVation-GS, have won seed grants from Grand Challenges Israel for their products to diagnose pneumonia in developing countries. The usual methods of diagnosing pneumonia in the developed world do not work well in developing countries due to lack of access to X-rays and noisy clinic environments. RespiDX has designed the Respimometer, a device that measures breathing and can be integrated into a regular digital thermometer. NanoVation-GS is developing a stick-on patch with a sensor to measure respiration rate. Both startups are using the grants to further develop their products and conduct tests in Africa. The goal of the program is to encourage Israeli entrepreneurs to find solutions for developing nations and open up business potential.
Customers
growth-positive
Catching pneumonia before it kills
Two Israeli startups, RespiDX and NanoVation-GS, have won seed grants to develop products for diagnosing pneumonia in developing countries. Pneumonia is a severe infection in the lungs that causes more deaths in children under five years old than AIDS, malaria, and measles combined. The usual methods of diagnosing pneumonia in developed countries do not work well in developing countries, where X-rays are not widely available and counting breaths per minute is not possible in noisy clinic environments. RespiDX has designed the Respimometer, a device that measures breathing and can be integrated into a regular digital thermometer. NanoVation-GS is developing a stick-on patch coated with a thin film of nanomaterial that measures respiration rate. The grants were awarded by Grand Challenges Israel, a program aimed at finding solutions for developing nations.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $8.76M |
| Last funding | $750K |
| Stage | Seed |
| Rounds | 7 |
| Investors | 3 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.nanovation-gs.com |
Locations
Khuri St 2, Haifa, Israel
Photos & Videos
2 item(s)
